Exai Bio, a next-generation company specializing in oncRNA and generative AI-based liquid biopsy technologies, has announced the publication of a peer-reviewed paper in Nature Communications. The study, titled “Deep generative AI models analyzing circulating orphan non-coding RNAs enable detection of early-stage lung cancer,” highlights the superior performance of Exai’s generative AI model in detecting lung cancer. The model outperformed traditional machine learning techniques, achieving higher sensitivity and specificity across all stages of cancer detection. Notably, Exai’s platform demonstrated a 30% improvement over other methods in validation datasets.
Exai Bio, a leader in generative AI-based liquid biopsy technology, announced the publication of its study in Nature Communications, showcasing the power of its platform in surpassing traditional liquid biopsy methods. Dave Daly, CEO of Exai Bio, stated, “This publication highlights Exai Bio’s generative AI platform and its ability to outperform commonly used methods in liquid biopsy. Our unique combination of AI and novel RNA biomarkers will be critical to advancing next-generation tests for early cancer detection.”
The study, involving 1,050 individuals with non-small cell lung cancer and non-cancer controls, demonstrated Exai’s deep generative AI model outperforming conventional machine learning methods, including support vector machines, ElasticNet, and XGBoost. Exai’s model not only excelled in overall performance but also showed improved generalizability and analytical properties when tested on held-out datasets.
Babak Alipanahi, Chief Scientific Officer of Exai Bio, commented, “This publication underscores the significance of generative AI in liquid biopsy, showing its robustness and performance compared to traditional machine learning methods. Our platform is set to play a pivotal role in the next generation of liquid biopsy applications.”
Exai’s platform leverages RNA sequencing to identify a novel class of cancer-associated, small non-coding RNAs (oncRNAs). These orphan non-coding RNAs are secreted by living cancer cells and are abundant in blood. When combined with Exai’s AI technology, oncRNAs offer superior sensitivity, specificity, and cost-effectiveness compared to circulating tumor DNA tests, while also capturing dynamic changes in a patient’s tumor biology over time.
About Exai Bio
Exai Bio is a next-generation liquid biopsy company focused on enabling early cancer detection, accurate diagnosis, and personalized treatment. The company’s proprietary oncRNA- and AI-based technology provides critical insights into cancer biology, facilitating the earliest and most precise diagnoses.
